ADCsessions in oncology 2022
Overview of the recent results and currentresearch of Antibody-Drug Conjugatesacross cancer types: breast, lung, gastrointestinal and genitourinary
Coordinators:
Dr. Eva Ciruelos(University Hospital 12 de Octubre (Madrid), HM Hospitales and Vice President of SOLTI)
Dr. Mafalda Oliveira (Vall d’Hebron Institute of Oncology (Barcelona) and SOLTI Governing Board Member)
16:00 – Welcome by coordinators
16:10 – Overview – ADCs in cancer
Speaker: Dr. Barbara Pistilli (Institut de Cancérologie Gustave Roussy, Paris)
Discussants: coordinators, Dr. Gail D. Lewis (Genentech, Roche, virtually)
16:45 – Target-based discussion tables
Novel TROP-2 approaches in cancer
Speaker: Dr. Aditya Bardia (Massachusetts General Hospital, virtual lecture)
Discussants: Dr. Ignacio Durán (Hospital Universitario Marqués de Valdecilla), Dr. Daejin Abidoye (Gilead), Dr. Gilles Gallant (Daiichi-Sankyo)
Strategies to overcome resistance in HER2 positive tumors
Speaker: Dr. Javier Cortés (International Breast Cancer Center)
Discussants: Dr. Enriqueta Felip (Vall d’Hebron Institute of Oncology, Barcelona), Dr. Andrés Cervantes (University Clinical Hospital of Valencia, virtual), Dr. Zeeshan Rasheed (AstraZeneca)
HER3 as a new biomarker in cancer
Speaker: Dr. Egbert Smit (Leids Universitair Medisch Centrum, Leiden, Netherlands, virtual lecture)
Discussants: Dr. Luis Paz-Ares (University Hospital 12 de Octubre, Madrid), Dr. Juan Miguel Cejalvo (University Clinical Hospital of Valencia), Dr. Gilles Gallant (Daiichi-Sankyo)
Other targets and drugs: nectin 4 and more
Speaker: Dr. Funda Meric-Bernstam (MD Anderson Cancer Center, virtual lecture)
Discussants: Dr. Daniel Castellano (University Hospital 12 de Octubre, Madrid), Dr. Emiliano Calvo (Centro Integral Oncológico Clara Campal), Dr. Valentina Boni (Quirónsalud, Madrid)
19:20 – Conclusions and closure
